Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | CHIEF SCIENTIFIC OFFICER | February 21, 2019 | February 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date February 21, 2019 · Filed February 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2029-02-21 | Direct | 12,751 |
Reported balance
After 2019-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-21 · Grant · Acquired 12,751 · Balance 12,751 F1: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2019 Filed Feb 23, 2019 00:43 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 12,751 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001415889-19-000227 · form4-02222019_040244.xml · derivative · entry 1 Roberts Matthew A · CIK 0001761147 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,751 Underlying: Common Stock · 12,751 shares Expires 2029-02-21 F1 · derivative.exercise_date: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 00:58 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001415889-18-001750 · form4-12112018_041214.xml · derivative · entry 1 Roberts Matthew A · CIK 0001761147 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on December 10, 2019, and the remaining shares subject to the option vest in a series of 24 equal monthly installments thereafter on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.